The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

Abstract

AbstractBackgroundConcomitant high‐dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin‐induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants.MethodsConducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty‐one SNPs that were previously associated with CIHL or other cisplatin‐induced toxicities were identified and incorporated into the model. The primary outcome measured was the change in decibels at posttreatment 1‐2‐4 kHz hearing levels per additional minor allele of these SNPs, evaluated using linear mixed‐effects regression models. The model's predictive accuracy was determined by the area under the curve (AUC) using 10‐fold cross‐validation.ResultsThe rs2289669 SNP in the SLC47A1/MATE1 gene was linked to a significant 2.67 dB increase in hearing loss per allele (95% CI 0.49–4.86, p = 0.017). Incorporating rs2289669 improved the model's AUC from 0.78 to 0.83, a borderline significant improvement (p = 0.073).ConclusionsThis study underscores the importance of the rs2289669 SNP in CIHL and demonstrates the potential of combining genetic and clinical data for enhanced predictive models in personalized treatment strategies.